Shortening treatment for tuberculosis - Back to basics

New England Journal of Medicine

Volumn 371, Issue 17, 2014, Pages 1642-1643

  Warner, Digby F ^a   Mizrahi, Valerie ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ETHAMBUTOL PLUS ISONIAZID PLUS RIFAMPIN; GATIFLOXACIN; ISONIAZID; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAPENTINE; UNCLASSIFIED DRUG; DRUG DERIVATIVE; QUINOLONE DERIVATIVE; TUBERCULOSTATIC AGENT;

DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESISTANT TUBERCULOSIS; DRUG SUBSTITUTION; DRUG SUSCEPTIBLE TUBERCULOSIS; DRUG WITHDRAWAL; EDITORIAL; ENDEMIC DISEASE; GRANULOMA; HEALTH CARE COST; HUMAN; INFECTION CONTROL; NONHUMAN; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RABBIT; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT INDICATION; TUBERCULOSIS; FEMALE; ISOLATION AND PURIFICATION; LUNG TUBERCULOSIS; MALE; MYCOBACTERIUM TUBERCULOSIS; NOTE;

ANTITUBERCULAR AGENTS; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MYCOBACTERIUM TUBERCULOSIS; RIFAMPIN; TUBERCULOSIS, PULMONARY;

EID: 84908120538     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1410977     Document Type: Editorial

References (10)

1. Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014;371:1577-87.
2. Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin- containing regimen for treating tuberculosis. N Engl J Med 2014;371:1588-98.
3. Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014;371:1599-608.
4. Rustomjee R, Lienhardt C, Kanyok T, et al. A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12:128-38.
5. Phillips PP, Gillespie SH, Boeree M, et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis 2012;205:Suppl 2:S250-S257.
6. Wallis RS, Wang C, Meyer D, Thomas N. Month 2 culture status and treatment duration as predictors of tuberculosis relapse risk in a meta-regression model. PLoS One 2013;8(8):e71116.
7. Irwin SM, Gruppo V, Brooks E, et al. Limited activity of clofazimine as a single drug in a mouse model of tuberculosis exhibiting caseous necrotic granulomas. Antimicrob Agents Chemother 2014;58:4026-34.
8. Lin PL, Coleman T, Carney JP, et al. Radiologic responses in cynomolgous macaques for assessing tuberculosis chemotherapy regimens. Antimicrob Agents Chemother 2013;57:4237.
9. Dartois V. The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells. Nat Rev Microbiol 2014;12:159-67.
10. Lenaerts AJ, Hoff D, Aly S, et al. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910. Antimicrob Agents Chemother 2007;51:3338-45.